Considering somatic variants, RET GoF pathogenic variants are found in approximately half of sporadic MTC cases (Ciampi et al. 2019), and activating RET chromosomal rearrangements or gene fusions constitute oncogenic drivers in multiple solid tumours, including 10–20% papillary thyroid cancers (PTCs) (Agrawal et al. 2014) and 1–2% of NSCLC (Takeuchi et al. 2012). Here, RET is linked to thyroid gland papillary carcinoma.